Amneal Announces Expanded Coverage for CREXONT® (Carbidopa and Levodopa) to Enhance Access for Parkinson’s Disease Patients in the U.S.

Amneal Pharmaceuticals (AMRX) announced Thursday that insurance coverage accounts, the Veterans Administration, ...

A proteasome inhibitor, Boruzu references branded Velcade, a lyophilised powder that requires reconstitution prior to usage.

Amneal and Shilpa are releasing Boruzu, a new presentation of bortezomib for ready-to-use subcutaneous administration or ...

The generic drug segment, a key driver of Amneal’s business, has shown particularly impressive growth. Analysts project a 17% growth for the generic segment in the third quarter of 2024 ...

Amneal Pharmaceuticals, Inc. offers strong growth prospects with undervalued stock, rising revenues, reduced debt, and key expansions. Read more about AMRX stock here.

Amneal Pharmaceuticals (NYSE:NASDAQ:AMRX), a commercial-stage biopharmaceutical company with a market capitalization of $2.74 billion, has been making significant strides in the pharmaceutical ...